"" Momenta could hear news about their generic Copaxone application at anytime. The Hatch-Waxman 30-month stay on an FDA decision is now over meaning the FDA can make a ruling regardless of the patent suit. Currently, Teva is in patent litigation against MNTA/NVS and Mylan over Copaxone. News is expected on this front sometime in the middle of 2011. Analysts think Momenta could get a favorable decision in these proceedings. If Momenta wins in court and obtains FDA approval, that would be monumental for their prospects.""
Market Data 
Markets 
AI
